Overview of Mildronat Grindeks

Mildronat Grindeks is a specific trade name for a pharmaceutical preparation whose active ingredient is the chemical compound Meldonium (INN). The drug is primarily classified as a Metabolic Modulator and is used therapeutically as a Cardioprotective Agent in regions including Eastern Europe, where it is widely clinically recognized for its anti-ischemic properties. It is a synthetic compound developed by the Latvian Institute of Organic Synthesis.

Property	Description
Active ingredient	Meldonium (INN)
Form	Oral capsules, Solution for injection
Pharmacological class	Metabolic Modulator / Anti-ischemic Drug
General purpose	Optimizing oxygen use in vulnerable tissues
Origin	Synthetic, developed in Latvia

1. What is Mildronat Grindeks and its Core Component?

Mildronat Grindeks, manufactured by the Latvian pharmaceutical company Grindeks, contains the active substance Meldonium, chemically known as 3-(2,2,2-trimethylhydrazinium)propionate dihydrate. This compound is a synthetic structural analogue of gamma-butyrobetaine, a natural precursor to L-carnitine. The preparation is presented as a single active ingredient product in two forms: oral capsules and a sterile solution for injection for intravenous use.

2. What Type of Medicine is Meldonium Classified as?

Meldonium is classified under ATC code C01EB22, a subcategory for Other Cardiac Preparations. It functions as an anti-ischemic drug and a Metabolic Modulator by altering how cells generate energy. Clinical pharmacological studies have documented its role as an inhibitor of L-carnitine synthesis, which is a differentiating feature from L-carnitine supplements. This mechanism allows the medicine to shift the cell's energy generation towards the more oxygen-efficient process of glucose metabolism.

3. What is the General Therapeutic Purpose?

The general therapeutic purpose of Meldonium is to induce a cytoprotective effect in tissues that are stressed by limited blood and oxygen supply, which is a typical concern for elderly individuals with ischaemic conditions. This protective action enhances the cellular endurance and resistance to damage caused by oxygen deprivation. The drug is clinically utilized to help maintain tissue function under periods of stress or increased demand.

What side effects are possible with Mildronat Grindeks?

Possible side effects and safety information

The safety profile for Mildronat Grindeks (Meldonium) is officially documented by government health authorities and categorized according to the affected body system and frequency of occurrence.

Documented Adverse Reactions

Adverse reactions are classified into categories based on frequency. Common reactions (occurring in 1 to 10 out of every 100 individuals) documented in the regulatory label primarily include Headache and various Allergic Reactions, which may manifest as blushing, skin rash, itching, or swelling. In the Very Rare category (less than 1 out of 10,000 individuals), the official labels list effects on the cardiovascular system, such as Tachycardia (fast heart rate) and Hypotension (decreased blood pressure).

Reactions are grouped into System-Organ Classes (SOC) including Immune System Disorders, Nervous System Disorders, Cardiac Disorders, and Vascular Disorders. Other documented reactions whose frequency is Not Known include agitation and eosinophilia.

Safety Constraints and Special Populations

Official regulatory documents define specific safety limitations. The medicine is Contraindicated in individuals with a known hypersensitivity to the active substance or in conditions associated with increased intracranial pressure.

Safety data is limited for certain groups. The medicine is not recommended for use in children and adolescents under 18 years of age due to an absence of clinical data on safety and efficacy in this population. Similarly, caution is advised for use in patients with chronic renal or hepatic impairment, as safety data for severe cases of these conditions are unavailable. High-level safety notes also indicate the product may enhance the effects of certain vasodilators or blood pressure-lowering medicines, posing a risk of hypotension.

This structure ensures the potential risks and constraints are clearly communicated within the official regulatory framework.

Overdose and Emergency Response

The official regulatory profile for Mildronat Grindeks (Meldonium) indicates the product is of low toxicity, and authorities state there are no data concerning overdose in humans. It is formally documented that the medicine causes no undesirable effects that would be dangerous to patient's health, distinguishing it from agents with high-risk overdose profiles.

When to Seek Help

Regulatory guidance mandates that individuals must contact their doctor immediately if a dose of Mildronat Grindeks higher than the prescribed amount is taken. This instruction is critical for managing any potential symptomatic effects.

Documented Manifestations and Management

While data on human overdose are unavailable, in situations of high exposure that lead to a significant drop in blood pressure (hypotension), manifestations may include headache, dizziness, increased heart rate (tachycardia), and a feeling of weakness.

The management approach is defined as symptomatic and supportive care, consistent with the fact that no specific antidote is known. The procedural instruction documented for severe effects is the use of arterial blood pressure regulating medicines if the patient's arterial pressure considerably deviates from normal. This approach focuses solely on addressing the physical signs of overexposure as they manifest.

Therapeutic Uses of Mildronat Grindeks

What Mildronat Grindeks treats: Main Uses and Benefits

The therapeutic application of Mildronat Grindeks (Meldonium) centers on addressing conditions where tissues are affected by reduced blood and oxygen supply, primarily in the cardiovascular and neurological systems. Its use aims to provide supportive relief and maintain functional stability during symptomatic periods.

The medicine is commonly used to help with symptoms related to conditions involving episodic or fluctuating manifestations, such as chronic heart ischemic disease (including stable angina pectoris and mild chronic heart failure), acute and chronic ischemic brain circulation disorders, and in settings marked by temporary physiological imbalance due to physical and emotional overload.

It is applied in clinical settings marked by increased discomfort or tension, providing support that helps ease the overall symptom burden. The medication's application is often related to the principle:

“It is relevant for easing symptoms that interfere with daily comfort and supports the patient during difficult episodes by easing distress.”

This focus on support assists with maintaining functional stability, which can contribute to improved comfort during periods of symptomatic activity and general physical exertion.

Quick Fact: Supportive Role in Functional Stress

Quick Fact: Supportive Role in Functional Stress. The medicine is commonly used to help with symptoms related to systemic imbalance and functional stress, such as asthenia (general weakness) and symptoms that interfere with daily functioning, often applied during phases when symptoms become more noticeable after an acute event or during chronic illness.

Regulatory References

Summary of Product Characteristics from a European regulatory authority

Eligibility and Restrictions for Use

Regulatory documents define strict eligibility and exclusion criteria for the use of Mildronat Grindeks, which contains the active substance meldonium.

Populations Excluded from Use

Classification	Population	Regulatory Basis
Contraindicated	Patients with known hypersensitivity to the active substance (meldonium dihydrate) or any excipients in the formulation.	Absolute Exclusion
Not Recommended	Children and adolescents (pediatric population).	Lack of safety and efficacy data
Not Recommended	Pregnant or breastfeeding individuals.	Lack of clinical data on safety during gestation and lactation

Use Restrictions and Special Considerations

The medicine is generally reserved for adults who do not fall into any of the above-listed non-eligible groups. However, special care is required for certain patients due to the body's process for eliminating the drug:

Chronic Liver and Renal Disease: Patients with pre-existing chronic liver or renal diseases should use this product with caution. Regulatory guidance suggests that dose reduction may be necessary for these patients due to the drug's elimination route.

The official eligibility profile prioritizes patient safety by formally excluding vulnerable populations where adequate safety data are absent and establishing an absolute prohibition for those with known allergies to the product's components.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Mildronat Grindeks (Meldonium) primarily defines its interaction profile through pharmacodynamic potentiation with other medicines used to treat cardiovascular conditions. This means that co-administration may lead to an intensified action of the co-administered drug. The potential for this intensified effect must be taken into consideration when Mildronat Grindeks is used alongside specific cardiovascular medicinal products.

Agent/Class	Official Interaction Statement
Hypotensive agents	May result in intensified action (Potentiation).
Glyceryl trinitrate, Nifedipine, Beta-adrenoblockers, and Peripheral vasodilators	May result in intensified action (Potentiation).

Conversely, the regulatory information notes that Mildronat Grindeks may be used together with several classes of cardiovascular medicines without explicit restriction, including antianginal medicinal products, anticoagulants, antiarrhythmics, diuretics, and cardiac glycosides.

Regarding non-medicinal products, the regulatory information notes that food slightly delays the absorption of the medicine but does not reduce its overall effect. No contraindicated combinations, pharmacokinetic enzyme effects, or mandatory timing separation rules are explicitly specified in the official interaction section.

Mechanism of Action

How Mildronat Grindeks Works

Energy Metabolism Modulation

This mechanism centers on the competitive inhibition of the enzyme gamma-butyrobetaine hydroxylase (BBOX), the final step in L-carnitine biosynthesis. By reducing L-carnitine tissue concentration, the drug restricts the transfer of long-chain fatty acids into the mitochondria for oxidation. This action shifts cellular energy production toward the more oxygen-efficient glucose oxidation pathway. The metabolic change assists in maintaining cellular ATP synthesis when oxygen availability is reduced, supporting cellular resilience in highly aerobic tissues.

Downstream Physiological Effects

The restricted rate of fatty acid breakdown limits the accumulation of partially metabolized long-chain acylcarnitines and other cytotoxic intermediates. This preserves the structural integrity of cellular membranes, including those of the mitochondria. Additionally, the drug induces the accumulation of the L-carnitine precursor, gamma-butyrobetaine (GBB). GBB accumulation stimulates the release of nitric oxide ( NO) from the vascular endothelium, resulting in vasodilation (widening of blood vessels), which influences systemic perfusion and oxygen transport.

Dosage and Administration Information

How to Use Mildronat Grindeks

The administration of Mildronat Grindeks (Meldonium) follows a defined route, dosage, and schedule for its use. The medicine is primarily available for oral administration as hard capsules, though a solution for intravenous use also exists.

Standard Dosing Protocol

The standard protocol defines a daily dosage ranging from 500 mg to 1000 mg of meldonium dihydrate. The maximum daily dose is 1000 mg. This daily quantity is typically administered once daily; however, the maximum 1000 mg dosage may be divided into two single doses.

To ensure proper administration, the capsules must be swallowed whole with water and should not be crushed or chewed. Administration is advised in the morning due to the drug's possible stimulating effects. The medicine may be taken with food to minimize potential gastrointestinal disturbances.

Duration and Specific Patient Rules

Mildronat Grindeks is used in a time-bound course with a typical duration ranging from four to six weeks. This course length governs the overall treatment period.

Specific rules apply to certain populations: for adults with renal or hepatic impairment, the dose is reduced because the medicine is primarily eliminated by the kidneys. Furthermore, its use is not recommended for the paediatric population (under 18 years) due to a lack of documented safety and efficacy data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mildronat Grindeks

The research base for Meldonium (the active ingredient in Mildronat Grindeks) consists primarily of clinical studies conducted in regions where the medicine is authorized, often exploring its use as an addition to existing standard therapies. The findings described below reflect patterns observed in specific study populations and settings.

Evidence for use in Chronic Ischemic Heart Disease

Research has explored the use of Meldonium in adults with stable angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. Studies included randomized controlled trials (RCTs), some of which were double-blind and placebo-controlled, often lasting for short- to intermediate-term observation periods, such as 12 weeks.

Researchers primarily examined outcomes related to physical discomfort and activity level, focusing on measures like total exercise time during bicycle ergometry and the frequency of angina attacks. Some placebo-controlled studies reported patterns of change in total exercise time over 12 weeks for some groups receiving the study drug compared to placebo. Other trials explored whether adding Meldonium to the basic regimen was associated with changes in antianginal action and physical performance.

Evidence for use in Chronic Heart Failure

Research explored the use of Meldonium in studies involving patients with chronic heart failure (CHF), including those with specific diagnoses like Right Ventricular Failure (RVF). Research explored short-term symptom changes and outcomes reflecting daily functioning, such as the 6-minute walk test (6MWT) and quality of life scores (SF-36).

Studies reported measurements of changes in 6MWT distance and shifts in WHO Functional Class over defined time intervals. Research exploring short-term symptom changes in patients with CHF also reported patterns observed in functional measures when the drug was part of a combination therapy. Data show patterns related to functional measures, but not all studies described changes in vital signs or blood biochemistry, such as BNP levels.

What is Still Uncertain About the Research Evidence

Evidence quality varies across studies, and some limitations are consistently noted in scientific reviews. For instance, the research is largely based on studies conducted in Eastern European and Baltic countries, meaning data for broader international populations remain limited and comparative evidence in other international medical settings is lacking. Scientific reviews suggest that while short-term data show patterns related to functional measures in certain patient groups, large-scale, international placebo-controlled trials are still needed to contribute to greater certainty regarding long-term effects across diverse populations.

Frequently Asked Questions (FAQ)

Common questions about Mildronat Grindeks (FAQ)

Q: What specific conditions is Mildronat Grindeks typically prescribed for?

Mildronat Grindeks is indicated as part of a combination therapy for various conditions, primarily those affecting the heart and blood vessels. According to official product information, this includes the adjuvant treatment of stable angina pectoris, chronic heart failure (CHF), and certain forms of chronic ischemic heart disease. The drug's mechanism of action is to support tissue resilience, particularly when blood flow and oxygen supply are limited.

Q: Does Mildronat Grindeks affect the body's use of L-carnitine?

Yes, Mildronat Grindeks influences the body's metabolism by acting as a competitive inhibitor of the enzyme that creates L-carnitine. By restricting L-carnitine biosynthesis, the medicine effectively reduces the transport of long-chain fatty acids into the cells' energy centers. This metabolic shift supports cellular energy production through the more oxygen-efficient glucose pathway, which is beneficial in tissues experiencing ischemia (lack of blood supply).

Q: Is Mildronat Grindeks the same as L-carnitine?

No, Mildronat Grindeks is not the same as L-carnitine; they are distinct compounds. Mildronat's active substance (meldonium) is a structural analogue of a precursor to L-carnitine, and its mechanism involves actively restricting L-carnitine production in the body.

Q: What are the concerns about using Mildronat Grindeks if a person has liver or kidney issues?

Regulatory information advises caution and dose reduction for patients with impaired renal (kidney) or hepatic (liver) function. This is because the medicine is eliminated from the body primarily by the kidneys. Safety data for individuals with severe liver or kidney conditions are currently not available, which necessitates careful medical oversight.

Q: Is there any research about Mildronat Grindeks and its effects on neurological conditions?

Yes, regulatory documents and clinical literature indicate that Mildronat Grindeks is indicated for the treatment of certain functional and ischemic disorders of the central nervous system (CNS). Studies have explored its use for conditions related to cerebral circulation. Additionally, effects on improving patients' mood, motor function, and reducing symptoms like dizziness have been noted in these contexts.

Q: Why do some people use Mildronat Grindeks for 'physical or psycho-emotional overload'?

While the drug's primary therapeutic indications are for cardiovascular and neurological conditions, patient information leaflets in some regions reference its use for reduced work capacity and states of physical or psycho-emotional overload. This usage relates to the drug's overall cytoprotective effect, which is designed to enhance cellular endurance and resilience when tissues are under stress or high demand.

Q: What are the research findings regarding Mildronat Grindeks and chronic heart failure?

Clinical studies have investigated the use of this medicine as part of a combination treatment for chronic heart failure. Research has reported patterns related to increased exercise tolerance and physical load size in patients. Functional measures, such as the 6-minute walk test, have been used in studies to observe these changes.

Q: Why is the drug advised to be taken in the morning?

Official product information advises taking the medicine in the morning. This is due to the potential for the drug to have a stimulating effect on the central nervous system, which, if taken later in the day, could potentially interfere with sleep.

Q: Is Mildronat Grindeks considered a vitamin, a supplement, or a prescription drug?

Mildronat Grindeks is classified as a prescription medicinal product. It is categorized as an anti-ischemic drug and a metabolic modulator containing the active pharmaceutical ingredient meldonium, not a vitamin or dietary supplement.

Q: In which countries is Mildronat Grindeks commonly used or approved?

Mildronat Grindeks is widely approved and commonly used in many countries. The largest presence and authorization for the medicine is typically found in Eastern European and Baltic states, where the manufacturing company holds the marketing authorization.

Q: What kind of research has been done on the long-term effects of Mildronat Grindeks?

Clinical studies supporting the drug's current indications typically involve short- to intermediate-term observation periods, such as a four-to-six-week course. Consequently, regulatory documents do not provide extensive data or conclusions regarding the continuous effects of very long-term use.

Q: Can women use Mildronat Grindeks while breastfeeding?

No, the use of Mildronat Grindeks is not recommended for women who are breastfeeding. This precaution is taken because it is not known whether the active substance is excreted in human breast milk, and safety in the nursing infant has not been established in clinical studies.

Q: Does taking Mildronat Grindeks affect a person's ability to drive or operate machinery?

Official documentation states that Mildronat Grindeks has no known influence on a person's ability to drive or safely use machines.

Q: Can Mildronat Grindeks affect stomach health or cause nausea?

While nausea is not typically listed as a common side effect in the official safety profile, patient information leaflets advise that the medicine can be taken with food. This recommendation is made to help minimize the potential for minor gastrointestinal disturbances.

Q: What is the typical age range for patients who are prescribed Mildronat Grindeks?

The medicine is officially indicated for use only in the adult population. It is not recommended for use in children and adolescents under 18 years of age due to a lack of documented safety and efficacy data in this age group.

Q: Does Mildronat Grindeks contain any common allergens or inactive ingredients to be aware of?

Yes, the official label includes a full list of all inactive ingredients, or excipients, in the formulation. The medicine is contraindicated (should not be used) in anyone with a known hypersensitivity or allergy to the active substance or any of the listed excipients.

Q: Is the research on Mildronat Grindeks mostly limited to Eastern European studies?

Scientific reviews of the available data consistently note that the body of research is largely comprised of studies conducted in Eastern European and Baltic countries. While these studies show functional patterns in certain patient groups, comparative evidence in other international medical settings is more limited.

Q: Does Mildronat Grindeks cause any significant changes to blood cell counts?

The official list of documented adverse reactions notes that eosinophilia, which is an increase in a specific type of white blood cell called eosinophils, has been reported. However, the frequency of this occurrence is listed as 'Not Known' because it cannot be accurately estimated from the available data.

How should Mildronat Grindeks be stored and disposed of?

Mildronat Grindeks must be stored under specific conditions established in regulatory documents to ensure product stability.

Storage & disposal scope	Official Regulatory Statement
Labeled storage temperature requirements	Store at a temperature not exceeding 25 C.
Light/moisture protection requirements	Store in the original package in order to protect from moisture.
Packaging-related storage rules	Store the product in the original package.
Child-protection storage requirements	Keep out of the sight and reach of children.
Disposal instructions	Dispose of unused medicinal product or waste material according to local requirements.

The official storage profile mandates a maximum temperature of 25 C, which is a condition for the product's labeled shelf-life. Keeping the medicine in the original packaging is required to ensure protection from moisture. Final handling instructions require that the product must be stored away from children and that disposal must strictly follow local regulations for discarding medicinal waste.

Mildronat Grindeks